Edwards Lifesciences Corp. — 2022 Form 10-K
Reporting period: Fiscal year ended December 31, 2022. This is an annual filing, not a standalone fourth-quarter report; quarterly Q4 results are not clearly provided in the supplied filing text.
Business context
Edwards develops and sells medical technologies for structural heart disease and critical care monitoring. Its product groups are Transcatheter Aortic Valve Replacement (TAVR), Transcatheter Mitral and Tricuspid Therapies (TMTT), Surgical Structural Heart, and Critical Care. TAVR accounted for 65% of sales. The company generated 58% of sales in the United States and 42% internationally.
Key financial metrics
| Metric | 2022 | 2021 | Change |
|---|---|---|---|
| Net sales | $5.382 billion | $5.233 billion | +2.9% |
| Gross profit / margin | $4.302 billion / 79.9% | $3.984 billion / 76.1% | Margin +3.8 percentage points |
| Operating income / margin | $1.749 billion / 32.5% | $1.690 billion / 32.3% | Income +3.4% |
| Net income | $1.522 billion | $1.503 billion | +1.3% |
| Diluted EPS | $2.44 | $2.38 | +2.5% |
| Operating cash flow | $1.218 billion | $1.732 billion | Down $513.9 million |
| Capital expenditures | $244.6 million | $325.8 million | Down $81.2 million |
Cash and cash equivalents were $769.0 million, with short-term investments of $446.3 million; long-term investments were $1.239 billion. Current assets were $3.096 billion and current liabilities $1.022 billion. Debt consisted of $600 million in 4.3% senior notes due 2028; the $750 million revolving credit facility had no borrowings outstanding. The company reported $1.6 billion of financing cash outflow, primarily from $1.727 billion of share repurchases.
Material changes versus 2021
- Sales growth was led by TAVR, up 2.8% to $3.518 billion. TMTT grew 35.1% to $116.1 million; Surgical grew 0.4% to $893.1 million; Critical Care grew 2.4% to $855.0 million.
- Foreign exchange reduced reported sales outside the U.S. by $133.9 million overall; management cited a $140.2 million adverse impact on TAVR sales outside the U.S.
- Gross margin improved, supported by a 3.6-percentage-point benefit from foreign-currency hedging. Operating cash flow fell, reflecting higher tax payments, inventory builds, and bonus payments.
- R&D expense rose to $945.2 million, representing 17.6% of sales. SG&A increased with resumed in-person commercial activity and higher field personnel costs.
- Net income included a $60.7 million special charge, primarily for impairment and exit costs after the decision to discontinue the HARPOON mitral repair program. Contingent-consideration gains were $35.8 million, versus $124.1 million in 2021.
Outlook, risks, and unusual items
- The filing provides no specific 2023 sales or earnings guidance. Management anticipated approximately $300 million of 2023 capital expenditures.
- Management cited COVID-related hospital capacity and staffing constraints, particularly in the U.S. early in 2022 and Japan in the second half, as well as foreign-exchange headwinds. It continued investment in TAVR, mitral and tricuspid therapies, and clinical studies.
- The IRS proposed an adjustment that could result in approximately $210 million of additional tax expense related to 2015–2017 intercompany transfer pricing. Edwards disputed the proposal; the matter was referred to the IRS Independent Office of Appeals. The company also disclosed $475.3 million of gross uncertain tax positions, primarily related to transfer pricing, and stated the ultimate impact could be significant.
- Edwards disclosed an ongoing review of potential FCPA issues involving business activities in Japan and other markets, voluntarily reported to the SEC and DOJ. It could not predict the outcome or financial impact.
- A patent lawsuit concerning SAPIEN 3 Ultra had no accrued amount because the company could not estimate the possible exposure. The company also had continuing Abbott settlement payments and estimated royalties through May 2024.
- Other key exposures include medical-device regulation and approval delays, clinical trial outcomes, product quality and liability, supplier concentration, reimbursement and pricing pressure, competition, cybersecurity, and currency movements.
Important facts for investors to verify
- Review the IRS transfer-pricing dispute, potential tax exposure, and status of the company’s uncertain tax positions.
- Track hospital staffing and procedure volumes, especially in the U.S. and Japan, and the effect of currency movements on reported sales.
- Assess TAVR growth and the commercial and clinical progress of TMTT products and trials.
- Verify the cash-flow trajectory, inventory levels, planned capital spending, and the effects of continued share repurchases.
- Monitor developments in the FCPA review, SAPIEN patent litigation, and Abbott settlement obligations.